Key result
Navitor THV shows similar early composite safety outcomes compared to Evolut THV.
Why the study?
Does the intra-annular Navitor THV compared to the supra-annular Evolut THV improve safety and efficacy in adults with severe aortic stenosis undergoing TAVI?
Cohort (n=541)
Yes
Does the intra-annular Navitor THV compared to the supra-annular Evolut THV improve safety and efficacy in adults with severe aortic stenosis undergoing TAVI?
The intra-annular Navitor THV and supra-annular Evolut THV demonstrated comparable early safety and mid-term mortality, with Navitor showing a lower risk of moderate or severe paravalvular leakage.
Answers are grounded in this paper and cite their sources.
Similar early safety with Navitor versus Evolut should not yet change practice; leaves open need for randomized confirmation of PVL differences.
Background Comparative data on safety and efficacy of intra- and supra-annular self-expanding heart valves (THV) for transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis (AS) is scarce. The FIRE TAVI study compared procedural in-hospital and mid-term outcomes of the intra-annular Navitor THV and the supra-annular Evolut PRO THV. Methods The retrospective, multicenter study enrolled patients with severe AS who underwent TAVI using Navitor or Evolut PRO. The primary composite safety endpoint included all-cause mortality, myocardial infarction, disabling stroke, life-threatening bleeding, major vascular complication, or acute kidney injury requiring dialysis until discharge. Secondary endpoints comprised pacemaker implantation, paravalvular leakage (PVL), and mean transvalvular gradient. Mortality was assessed 381 ± 308 days after TAVI. Multivariable regression analysis was used for endpoint comparison of both THVs. Results Then, 269 patients after Navitor and 272 patients after Evolut PRO implantation were enrolled. There was no significant risk difference regarding the adjusted primary safety endpoint (OR 0.97 [95% CI 0.50–1.89]) and rate of pacemaker implantation (OR 1.13 [95% CI 0.67–1.90]). The pressure gradient was comparable between both groups (Navitor 7.0 [4.0–10.0] mmHg vs. Evolut PRO 6.0 [2.0–10.0] mmHg, mean difference − 0.32 [95% CI -0.97–0.32]). Navitor showed a lower frequency of more than mild PVL (0.8% vs. 3.5%, p = 0.032). Mortality was similar (HR 1.04 [95% CI 0.66–1.63]). Conclusion The implantation of the intra-annular Navitor and the supra-annular Evolut PRO was safe, with severe adverse events occurring at similar rates until discharge. The risk of moderate or severe PVL was lower with Navitor; mid-term mortality was comparable in both groups. Graphical Abstract The FIRE TAVI study compared patients with Navitor and Evolut platforms and showed that the implantation of the intra-annular self-expanding Navitor THV and the supra-annular self-expanding Evolut THV was safe and severe adverse events occurred with comparable frequency until discharge. Navitor patients presented a lower risk of moderate or severe PVL at discharge. The adjusted analysis included the following parameters: center, sex, age, BMI, Society of Thoracic Surgeons (STS) score, New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), mitral and tricuspid regurgitation, estimated glomerular filtration rate (eGFR), right bundle branch block (RBBB), coronary artery disease, prior stroke, chronic obstructive pulmonary disease, atrial fibrillation or flutter, peripheral artery disease, pulmonary hypertension, and transfemoral access. CI, confidence interval; HR, hazard ratio; OR, odds ratio; SEV, self-expanding valve; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart valve; PVL, paravalvular leakage. Illustration of the Evolut THV provided by Medtronic
No takes yet. Share an insight, caveat, or question.
Mattig et al. (2026) conducted a cohort in Severe aortic stenosis (n=541). Intra-annular Navitor THV vs. Supra-annular Evolut THV was evaluated on Composite safety endpoint (all-cause mortality, myocardial infarction, disabling stroke, life-threatening bleeding, major vascular complication, or acute kidney injury requiring dialysis until discharge) (OR 0.97, 95% CI 0.50-1.89, p=0.224). The intra-annular Navitor THV demonstrated a similar risk of the composite primary safety endpoint until discharge compared to the supra-annular Evolut THV.
Synapse has enriched 10 related papers. Consider them for comparative context: